Journal
HEALTH AFFAIRS
Volume 28, Issue 1, Pages W151-W160Publisher
PROJECT HOPE
DOI: 10.1377/hlthaff.28.1.w151
Keywords
-
Ask authors/readers for more resources
Annual growth in real prescription drug spending averaged 9.9 percent during 1997-2007 but has slowed since 2003, falling to 1.6 percent in 2007. More patent expirations, increased generic penetration, and reduced new product innovations have contributed to this turning point. We document trends and identify underlying components: declines in the role of blockbuster drugs, increased importance of biologics and vaccines relative to traditional pharmaceuticals, and a changing medication mix away from those prescribed principally by primary care physicians toward those mostly prescribed by specialists. We conclude with policy implications. [Health Affairs 28, no. 1 (2009): w151-w160 (published online 16 December 2008; 10.1377/hlthaff.28.1.w151)]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available